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Background: There is a need for evidence of the clinical effectiveness of minimally invasive surgery for the
treatment of esophageal cancer, but randomized controlled trials in surgery are often difficult to conduct. The
ROMIO (Randomized Open or Minimally Invasive Oesophagectomy) study will establish the feasibility of a main trial
which will examine the clinical and cost-effectiveness of minimally invasive and open surgical procedures for the
treatment of esophageal cancer.
Methods/Design: A pilot randomized controlled trial (RCT), in two centers (University Hospitals Bristol NHS
Foundation Trust and Plymouth Hospitals NHS Trust) will examine numbers of incident and eligible patients
who consent to participate in the ROMIO study. Interventions will include esophagectomy by: (1) open gastric
mobilization and right thoracotomy, (2) laparoscopic gastric mobilization and right thoracotomy, and (3) totally
minimally invasive surgery (in the Bristol center only). The primary outcomes of the feasibility study will be
measures of recruitment, successful development of methods to monitor quality of surgery and fidelity to a
surgical protocol, and development of a core outcome set to evaluate esophageal cancer surgery. The study will
test patient-reported outcomes measures to assess recovery, methods to blind participants, assessments of surgical
morbidity, and methods to capture cost and resource use. ROMIO will integrate methods to monitor and improve
recruitment using audio recordings of consultations between recruiting surgeons, nurses, and patients to provide
feedback for recruiting staff.
Discussion: The ROMIO study aims to establish efficient methods to undertake a main trial of minimally invasive
surgery versus open surgery for esophageal cancer.
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Trial registration: The pilot trial has Current Controlled Trials registration number ISRCTN59036820 (25/02/2013) at
www.controlled-trials.com; the ROMIO trial record at that site gives a link to the original version of the study protocol.
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Randomized controlled trialBackground
Esophageal cancer is the ninth most common cancer in
the United Kingdom (UK), and around 8,000 people are
newly diagnosed with the disease each year [1]. Surgery
alone or in combination with chemotherapy or chemo-
radiation treatment is the mainstay of cure for localised
esophageal adenocarcinoma and one of several options
for esophageal squamous cell cancer, which may also
be radically treated with definitive chemoradiotherapy
or radiotherapy alone. Esophagectomy for esophageal
cancer is a major procedure. Audit data for 1220
esophagectomies carried out in England and Wales
from April 2011 to March 2012 showed that 29.7% of
patients would experience a complication while 8.9%
would experience serious morbidity requiring a re-
operation [2]. The thirty-day mortality rate is 1.7% [2].
Esophagectomy also has a major short-term detrimen-
tal impact on health-related quality of life (HRQL),
with patients reporting a reduction in physical and
social function and marked increases in fatigue, breath-
lessness, and pain scores for at least three months after
surgery [3,4] and persistent long-term deficits can
occur [3]. These morbidities need to be considered
alongside the evidence that esophagectomy offers long-
term survival in the region of 20 to 40% [5-7].
There are several approaches for the resection of
esophageal tumors. Surgery may involve two or three
phase procedures (abdominal, chest and/or neck inci-
sions) or a transhiatal approach (abdominal and cervical
incision); each of these may be performed with minimal
access or open approaches. The past decade has seen a
growing interest in minimal access surgical techniques
for all types of cancer surgery, with the potential advan-
tages of causing less tissue trauma and better recovery.
In England and Wales, 43% (492 out of 1140) of esopha-
gectomies performed during the period of the recent
national audit used minimal access surgical techniques
[2]. These were mostly (321 out of 492, 65%) laparoscop-
ically assisted two-phase approaches (minimal access
approach for the abdomen and standard open right chest
incision), with the others being totally minimally invasive
esophagectomy (MIO). The audit data suggested that
length of hospital stay and inpatient complication rates
following open and minimal access approaches were simi-
lar, with the small differences observed being consistent
with chance. The biggest difference was in respiratorycomplications, the rate of which was observed to be lower
in MIO (11%, 18 out of 171 assuming no missing data)
than in open procedures (17%, 108 out of 647), a differ-
ence which is unlikely to occur by chance (P = 0.047,
chi-square test), but the interpretation of this finding
is complicated by the highest rate of respiratory com-
plications occurring following the hybrid procedures
(22% 70 out of 321). This is one example of the complex
data that can result from observational studies, where
the different procedures may be undertaken by surgeons
with different levels of experience and in patients
selected for particular interventions with different base-
line prognostic factor (for example age, fitness, and
tumor stage) profiles.
Whilst a number of systematic reviews have been
conducted, these all focus on data from observational
studies [8-17]. Such studies are subject to the same
caveats as stated above, and whilst they suggest that
minimally invasive techniques may improve short-term
clinical outcomes (such as morbidity and physiological
measures) [18] and reduce impact on HRQL during
recovery [19], these results must be interpreted with
caution. Furthermore, even these weak studies tell us
little about long-term survival [20], cost effectiveness,
and impact on long-term HRQL [8,21].
There are a limited number of small randomized tri-
als, including the recently reported Dutch TIME trial
(Traditional invasive versus minimally invasive esopha-
gectomy), which compared open two or three phase
esophagectomy (56 patients) with totally MIO (59 patients)
and reported short-term outcome data [22]. The trial
provided evidence that minimally invasive esophagec-
tomy was associated with a lower incidence of in-
hospital pulmonary infection (12% versus 34%) and a
shorter hospital stay (median 11 days versus 14 days)
compared to open surgery. The trial report was followed
by a critical correspondence from the surgical commu-
nity [23-26], much of which reflected a failure to appre-
ciate the pragmatic approach necessary to evaluate
complex interventions [27]. At the time of writing, the
French MIRO (oesophagectoMIe pour cancer paR voie
conventionnelle ou coeliO-assistée) trial is in progress,
randomly allocating 200 patients between open and
laparoscopically-assisted esophagectomy. Again the focus
will be on short-term complications (major morbidity
within 30 postoperative days) [28]. Whilst both the TIME
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for a larger multicenter trial that is designed to assess the
longer-term clinical effectiveness of minimally invasive
surgery. This trial needs to have a sufficient sample size
to demonstrate that any advantages of the minimally
invasive procedure for recovery and longer-term HRQL
are achieved without compromising the survival bene-
fits of surgical intervention.
There are a number of challenges to conducting ran-
domized controlled trial (RCT) evaluations of novel in-
terventions which need highly skilled operators, and
further problems to overcome in evaluations of surgery
in particular [29]. These include the anxiety patients
may have with leaving a decision between what can be
quite different interventions to chance, ensuring a fair
comparison between novel and standard techniques
when surgeons are refining their skills in the former as
the trial progresses, and keeping the patient and other
assessors of outcome blind to individual treatment
allocations, at least for the initial assessments of recovery.
There is no doubt that patients undergoing esophagec-
tomy are subject to a ‘complex intervention’, commonly
defined as an intervention comprising multiple interact-
ing aspects [30]. It is increasingly accepted that evalua-
tions of such complex interventions should be preceded
by feasibility work to establish if a main trial can recruit
sufficient participants within an acceptable time, to
standardize the interventions and establish criteria for
their adequate implementation, and to establish the most
appropriate measures of outcome for the main trial.
This protocol paper describes the ROMIO (Randomized
Oesophagectomy: Minimally Invasive or Open) study in
which we aim to standardize minimally invasive proce-
dures for esophagectomy in order to refine our approach
to evaluating MIO compared to open procedures in a
RCT, and to determine the feasibility of a multicenter
trial comparing the clinical and cost-effectiveness of
minimally invasive and open surgical procedures in pa-
tients with cancer of the esophagus. The specific objec-
tives of the ROMIO feasibility study are listed below.
List of ROMIO feasibility study objectives
(i) pilot the randomization process and investigate
difficulties affecting recruitment;
(ii) establish the proportion of patients who are
potentially eligible and successfully recruited to
inform sample size calculations for the main trial;
(iii) document in detail, using IDEAL recommendations
[31], the technical developments of totally MIO to
inform the design and choice of interventions in
the main trial;
(iv) develop a manual for optimizing pathology
procedures and reporting, including lymph nodecounts and ascertainment of positive resection
margins, which are likely to be short-term outcome
measures for the main trial;
(v) consider the appropriate statistical model for
estimating treatment effectiveness;
(vi) develop and evaluate feasible, acceptable, and
effective methods of blinding patients for the
first week postoperatively, so reducing bias in
self-reported outcomes; and
(vii) establish outcome measures for the main trial that
enable a comprehensive, valid, and reliable
assessment of esophagectomy outcome, and which
include a set of core outcome measures considered
to be essential in clinical effectiveness RCTs of
esophageal cancer surgery.
Methods/Design
ROMIO is a two-year external feasibility study with a
pilot parallel group RCT at its core. The pilot trial is
recruiting at two UK centers: University Hospitals
Bristol NHS Foundation Trust and Plymouth Hospitals
NHS Trust. Both centers have a team of upper gastro-
intestinal cancer surgeons (six in Bristol and five in
Plymouth) and each undertake 50 to 100 resections for
esophago-gastric cancer per year.
Participants
All referrals of patients with esophageal cancer or
high-grade dysplasia requiring surgery for primary
esophagectomy or neoadjuvant chemotherapy before
esophagectomy at the Bristol and Plymouth centers are
considered for eligibility. Patients recommended for
neoadjuvant chemotherapy and surgery are registered
in the screening log but full eligibility is only confirmed
once chemotherapy is completed, restaging undertaken,
and the multidisciplinary team (MDT) of clinicians
confirms that they will proceed to surgery. At this point
eligible patients are informed about the trial and invited
to have the method of their esophagectomy randomly
selected from between open gastric mobilization and
right thoracotomy, laparoscopic gastric mobilization
and right thoracotomy, or (Bristol center only) totally
minimally invasive surgery (Figure 1).
Inclusion criteria
Participants may enter the study if ALL of the following
apply: (1) male or female patients, (2) over 18 years of
age, (3) referred by the MDT for primary esophagectomy
or esophagectomy following restaging after neoadjuvant
chemotherapy (of any type including chemoradiotherapy),
(4) confirmed histopathological evidence of esophageal or
esophago-gastric junctional adenocarcinoma, squamous
cell cancer, or high-grade dysplasia, (5) fit for preoperative
anaesthesia and surgery, assessed by the MDT, (6) able to
Figure 1 Flow diagram showing process of recruitment to the ROMIO pilot randomized controlled trial. MDT, multidisciplinary team.
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urement before chemotherapy that the tumor starts
more than 5 cm below the crico-pharyngeus, (8) endo-
scopic measurement before chemotherapy that the tumor
involves less than 4 cm of the gastric wall, and (9) the final
pretreatment tumor stage is between high-grade dysplasia
and T4aN1M0.
Exclusion criteria
Participants may not enter the study if any of the fol-
lowing apply: (1) stage 4 disease, (2) type three tumors
of the esophago-gastric junction that are scheduled
for total gastrectomy, (3) patients with squamous cell
cancer of the esophagus who the MDT recommends for,
or who individually elect to undergo, definitive chemo-
radiotherapy, (4) evidence of previous complex thora-
cotomies or laparotomies, (5) evidence of previous orconcomitant malignancy that would interfere with this
treatment protocol, (6) pregnancy, (7) patients participat-
ing in other trials that would interfere with the implemen-
tation of this protocol at a particular study center.
Randomization
Internet-accessed randomization is conducted centrally
at the Bristol Randomized Trials Collaboration (BRTC), a
UK Clinical Research Collaboration registered Clinical Tri-
als Unit hosted by the University of Bristol. Randomization
within blocks of varying size is conducted separately for
the two centers and further stratified by whether the
patient has undergone neoadjuvant treatment or not. In
Bristol, patients are randomly allocated in a 1:1:1 ratio to
one of three arms: open esophagectomy (open gastric
mobilization and right thoracotomy), laparoscopic-assisted
esophagectomy (laparoscopic gastric mobilization and
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In Plymouth, randomization is restricted to two of the
study arms, open esophagectomy or laparoscopic-assisted
esophagectomy (Figure 1), in a 1:1 ratio. Patients must
be logged into the trial and issued with a unique study
ID number prior to the treatment allocation being gen-
erated, so ensuring judgments about eligibility are made
without knowledge of what the next allocation will be
(allocation concealment).
Trial interventions
During the trial the surgical procedures are carried out
under general anaesthesia with all patients receiving
antibiotic and deep vein thrombosis (DVT) prophylaxis
according to local hospital policies. The surgical proce-
dures last between 5 and 8 hours. For the purposes of this
pragmatic trial each intervention is allowed to be imple-
mented according to the standard local policy, so long as
there is consistency with the aspects of each intervention
the study team currently consider as mandatory or prohib-
ited for the particular method, as described below. This
approach will be formalized in a process evaluation during
this feasibility study leading to the production of an inter-
vention manual and an assessment of the adequate stand-
ard of, and fidelity to, each procedure undertaken. The
process evaluation will consider the surgical intervention
itself and concomitant interventions.
Open esophagectomy
In the ROMIO feasibility study the operation consists of
a two-phase esophagectomy (abdomen and right chest)
with a two-field lymphadenectomy (abdomen and thorax)
and involves two key steps or phases.
Abdominal phase
The incision (midline or subcostal) is at the surgeon’s
discretion. Complete gastric mobilization will be performed
based on the right gastroepiploic and right gastric arteries.
Pyloroplasty, pyloromyotomy, or no drainage is at the sur-
geon’s discretion. Lymphadenectomies are performed along
the common hepatic artery and the left gastric and splenic
artery either en bloc or separately, and removal of sufficient
crural fibres and a cuff of diaphragm performed if required
for tumor clearance. The pericardial fat pad and strips of
pleura are removed. Transection of the lesser curve may be
undertaken or left to the thoracic phase of the operation.
Placement of a feeding jejunostomy or naso-jejunal tube
is at the surgeon’s discretion as are placement of intra-
abdominal and intra-thoracic drains. Methods to close the
abdomen are at the surgeon’s discretion.
Thoracic phase
The chest is opened through a right thoracotomy and
the mediastinal pleura overlying the esophagus excisedin continuity with the esophagus. The posterior limit of
the dissection should be the antero-lateral wall of the
aorta. The thoracic duct is mobilized en bloc or separ-
ately to the esophagus and periesophageal tissues. The
thoracic duct is ligated and divided at the level of the
diaphragm. The esophagus is mobilized to the level of at
least the aortic arch or higher if required. The para-
esophageal and diaphragmatic nodes are removed in
continuity with the esophagus. The lymph nodes at the
tracheal bifurcation and along the right and left main
bronchi to the pulmonary hilus can be removed en bloc
or separately at the surgeon’s discretion. The anasto-
motic technique and method of chest drainage is at the
surgeon’s discretion. Methods to close the chest are at
the surgeon’s discretion.
Laparoscopically assisted esophagectomy
This operation consists of identical steps as described for
the open esophagectomy, but access to the abdominal cav-
ity is achieved with four or five 10 or 5 mm incisions and
surgery performed laparoscopically. Placement of a feed-
ing jejunostomy is at the surgeon’s discretion and may
be performed laparoscopically or by extending a port
site to an 8 cm abdominal incision. The thoracic part of
the operation is performed as described for the open
esophagectomy.
Totally minimally invasive esophagectomy
This consists of performing the steps of the abdominal
and chest phases of the operation as described for the
open esophagectomy. These are performed with abdom-
inal and chest ports positioned by the surgeon at their
discretion. Within the ROMIO feasibility study it is also
possible to perform a three phase procedure (undertaking
the anastomosis with a left cervical incision). Surgeons
in Bristol undertaking the totally minimally invasive
procedure are recording variations to this outlined
approach, with reasons, during this feasibility study to
inform the design and interventions to be evaluated in
the main trial.
Concomitant interventions and the enhanced recovery
protocol
Concomitant interventions are defined as naturally
accompanying or associated elements of the surgical
intervention itself, and can be divided into preope-
rative, perioperative and postoperative components.
Concomitant interventions to be considered as part of
the process evaluation during the pilot trial include the
anaesthetic and other perioperative procedures, imme-
diate postoperative care (including intensive care man-
agement), and patient rehabilitation, input from allied
health professionals such as physiotherapists and dieti-
cians, which may or may not be encompassed into a
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feasibility study standard protocols for follow-up care
after both procedures will be developed to minimize
the risk of performance bias arising from carers
differentially providing co-interventions in the main
trial.
This work will inform development of an enhanced
recovery pathway or manual to be used in the main trial
to provide the minimum standard of care permitted.
Together with the surgical intervention itself, concomi-
tant interventions will be considered during the process
evaluation and incorporated into the manual if identified
as important.
Outcome measures
The primary outcome for the main trial is currently
planned to be patient-reported physical fatigue, as mea-
sured by the Multidimensional Fatigue Inventory MFI-20
[32,33] measuring fatigue at several time points during the
first three months post-surgery; the speed of recovery of
each patient will be captured.
During the pilot trial we are asking participants to
complete a range of measures which are being consid-
ered as secondary outcome measures for the main trial
[34-36]. These are listed below. In addition, post-surgery
morbidity will be classified according to both the Accor-
dian and Clavien-Dindo schemes [37,38].
List of pilot trial secondary outcome measures
Date and cause of death
Disease recurrence with date
Lung function
Patient completed visual analogue scale assessment of
pain
Patient completed questionnaires on generic HRQL:
EuroQoL EQ-5D-5 L
Patient completed questionnaires on disease-specific
HRQL: European Organisation for Research and Treat-
ment of Cancer Core Quality of Life Questionnaire
(EORTC QLQ-C30) and the esophageal specific module
(QLQ-OES18)
Development of a core clinical outcome set for
esophageal cancer surgery
The ROMIO feasibility study provides the opportunity
to develop a core outcome set for esophageal cancer
surgery [39,40]. A core outcome set is a standardized set
of clinical outcomes that represents the minimum that
should be measured and reported in all clinical trials
[40]. A relatively long list of potential outcomes will be
generated by surveying patients and clinicians, which
will be reduced to those considered crucial and distinct-
ive through a Delphi exercise. This work will link with
'COMET' (Core Outcome Measures in EffectivenessTrials), funded by the Medical Research Council ConDuCT
(Collaboration and innovation in difficult randomized
controlled trials) Hub for Trials Methodology Research
and North West Hubs for trials methodology research
[40]. The final core set of outcomes for esophageal can-
cer surgery is expected to be less than 10 items.
Development of resource use data collection
During the ROMIO study best methods for capturing
cost and resource use in relation to the interventions
and follow-up in secondary care are being established.
Questionnaires are also being developed in order to
collect information about the use of primary NHS ser-
vices and social services and direct and indirect costs
incurred by patient and carers. The average costs for all
the different categories will be compared by study arm
to enable the main cost drivers of the interventions to
be established and compared. Any areas where obtaining
accurate estimates of costs is problematic will also be
identified. This will allow a more focused collection of
resource use data and a more accurate estimate of cost-
effectiveness in the main trial.
Data collection
Socioeconomic details and height are measured when
the patient is seen for a pre-surgery assessment only.
Lung function measurements and assessments of pain
are taken pre-surgery, during the first week post-surgery,
and at days three and six as a minimum. HRQL is
assessed using standardized questionnaires pre-surgery
and at 6, 42, 90, and 185 days; questionnaires are posted
with a stamped addressed envelope when necessary.
Resource use is assessed through medical records re-
view and interviews with patients.
Through medical records review, routine clinical mea-
sures are also captured whenever they are taken as part
of the patient’s care during the six month study period.
Clinical report forms designed for the study are used to
formalize this data collection. Measures of the surgical
process (for example blood loss or duration of surgery)
and pathological assessment of the tumor and lymph
nodes are included in this collection.
Sample size calculation and statistical analysis
In the feasibility study recruitment is occurring ini-
tially over a 12-month period, with 72 potentially
eligible patients expected during that time. This will
allow a true 50% recruitment rate to be estimated with
a 95% confidence interval of approximately 38 to 62%.
If 11 patients are randomly allocated to each surgical
procedure this will allow a true difference of 1.25
standard deviations between two procedures on a
continuous measure of early outcome to be detected
with 80% power at the 5% significance level. Hence the
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the recruitment rate to inform plans for the main trial,
and may provide evidence suggesting that a particular
method may be achieving relatively poorer short-term
outcomes and may need to be refined before proceeding
to the main study.
Summary statistics that will inform plans for the main
trial will be presented, including (in a CONSORT chart
format) the number of potentially eligible and confirmed
patients per month per center and the percentage of
patients agreeing to randomization and completing out-
come measurements. Mean scores on short-term out-
come measures will be presented for each study arm,
with P values and 95% confidence intervals presented
for treatment comparisons where at least 10 patients
have been randomized to each study arm. No conclu-
sions about the relative clinical effectiveness of the three
interventions will be drawn from these results; they will
purely inform the refinement of the interventions prior
to proceeding to the main trial. Additional summary
statistics will arise from the pilot work, for example,
mean scores on the blinding scale achieved by different
blinding procedures.
Quality control of surgery and development of the
surgical manual
Only surgeons or trainees under direct supervision
perform the procedures. A sample of procedures is
being video recorded for analysis by the research team
at Imperial College London. This will inform the devel-
opment of the following resources for the main trial:
(1) a surgical manual to define the framework for the
steps of each trial intervention and describe acceptable
and prohibited (unacceptable) protocol deviations; (2)
an esophageal competency-assessment tool (O-CAT)
based on the Observational Clinical Human Reliability
Assessment (OCHRA) techniques to assess the level of
competency for technical surgical performance [41],
including adherence to procedural steps, protocol de-
viations, errors, and near miss events; and (3) a manual
to describe details of concomitant interventions, such as
type of anaesthesia, pre- and postoperative rehabilitation,
and key elements of enhanced recovery pathways which
are important in fulfilling the CONSORT criteria for
reporting evaluations of complex interventions [30].
Pathological specimens are processed in an agreed uni-
form manner in both centers and dissection of lymph nodes
from the main specimen and lymphadenectomy specimens
follow a pro forma. These processes are reviewed regularly
in both centers and standardized techniques for sampling
lymph nodes are adopted so that the maximum yield can
be obtained from all cases. Involvement of the surgical
resection margin is assessed both microscopically and
macroscopically.Blinding patients
Methods to achieve blinding of patients and outcome
assessors to the type of surgery during the initial post-
surgery period are being piloted. In the first seven days
post-surgery patients are blinded by using large adhe-
sive dressings that are positioned similarly on all trial
patients regardless of the type of surgery (covering the
abdominal, thoracic, and cervical incisions). Patients
are asked to turn their head away during dressing
changes and on days two and six they are asked to
complete the Bang Blinding Index, which assesses
blinding success by asking patients to guess their arm
allocation [42]. The Bang Blinding Index is adminis-
tered by ward or nursing staff not routinely involved in
the patient’s care. Patients’ experiences of blinding and
experiences of ward staff and nurses involved with
these processes are being further explored in qualitative
interviews described below.Recruitment investigation
The ROMIO trial compares different surgical proce-
dures that are in common use in specialist centers, and
therefore the trial is likely to face a number of recruit-
ment challenges. Based on previous works by de Salis
et al. and Donovan et al. [43-49], a key component of
the pilot trial is an integrated qualitative study which is
exploring these challenges to inform the design of the
main ROMIO trial. Interviews with members of the
trial management group, principal investigators and ac-
tive recruiters explore their own views about the trial
including their knowledge of the evidence and equi-
poise, and any recruitment challenges expected or
experienced. The patient pathway is mapped through
recruitment and appointments are audio recorded to
scrutinize information provision and identify issues
potentially affecting trial recruitment along that path-
way. This will inform the development of information
and training programs for the main trial. Finally, inter-
views with a sample of eligible patients will explore
patient perspectives of surgery, previous experiences
with treatments, views about surgery, and the accept-
ability of randomization between the procedures.
Emerging issues related to trial design and conduct
that may be hindering recruitment are discussed be-
tween the trial team and a plan to improve recruit-
ment during the pilot trial will be introduced if
necessary. This may include reconsideration of eligi-
bility criteria, study information, advice about present-
ing the study, discussions about equipoise or evidence,
issues with patient pathways, and logistical issues in
particular centers. These may be addressed by changes
to study information or the protocol, or training for
recruiters.
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Ethical approval was granted by the South West -
Frenchay Research Ethics Committee (12/SW/0161).
Informed consent is obtained from each participant in
the ROMIO study.
Discussion
Currently, there is a lack of published data from RCTs
to support the patient benefit of minimally invasive sur-
gery for esophageal cancer. The well-known challenges
with conducting surgical trials need to be overcome to
ensure that a multicenter pragmatic trial can be carried
out efficiently. The ROMIO pilot trial has been de-
signed as a necessary precursor to a main trial, during
which the methodology and infrastructure for a trial will
be established.
To have impact on clinical practice we anticipate that
the main study will need to demonstrate more rapid
recovery following MIO and the hybrid procedure
compared to open esophagectomy, whilst showing that
the same survival benefits are achieved. In the follow-
ing illustrative calculations it is assumed that the
between-center variation in outcome is accommodated
by an intra cluster correlation of 0.1, and that each
center will recruit 40 participants [50]. With the antici-
pated primary outcome measure of fatigue, the MFI-20
[32,33], 425 patients in each group would allow a dif-
ference of one half of a standard deviation to be dem-
onstrated when comparing two treatment groups, with
90% power at the 5% significance level. Based on a
one-sided 95% confidence interval, this sample size
would also allow an absolute mortality risk difference
at 12 months of 15% or more to be ruled out, with 80%
power, when comparing the minimally invasive (22.5%
mortality) to the open procedure (7.5% mortality).
The ROMIO pilot study has been designed to allow cen-
ters to opt to recruit into a two or a three arm study.
Where the three arm trial has been performed, the tech-
nique for totally minimally invasive surgery has been
deliberately allowed to evolve during the pilot study to
document the technical changes and outcomes. Whether
a totally minimally invasive approach can be used in many
centers in the main trial is uncertain because it is not
widely practiced in the UK. The final design of the main
trial, therefore, will be considered by the trial oversight
steering group in discussion with the trial management
group and be selected to reflect current UK practice and
emerging evidence.
Trial status
The ROMIO feasibility trial recruited and randomized the
first patient in April 2013. Recruitment is above the
expected target and the feasibility work will be completed
on schedule. The main trial is under design at present.Abbreviations
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